Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

WHITEHOUSE STATION, N.J. – Merck & Co.’s first-quarter profit rose 7 per cent, as heavy cost-cutting offset lower sales due to generic competition and a tax benefit in last year’s quarter.
The maker of the type 2 diabetes pill Januvia says net income was $1.71 billion, or 57 cents per share, up from $1.59 billion, or 52 cents per share, a year earlier.
Excluding one-time items, net income would have been $2.6 billion, or 88 cents per share. Analysts surveyed by FactSet were expecting 79 cents per share.
Revenue totalled $10.26 billion. Analysts expected $10.44 billion.
Merck, based in Whitehouse Station, N.J., reaffirmed its 2014 forecast for profit of $2.15 to $2.47 per share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.